Myfortic (mycophenolic acid)

Manufacturer:
Novartis
Route of Administration: 
Oral
Site of Care:
Outpatient
Website: 

    Approved Indication:

    prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant, in combination with other immunosuppressants

    Conditions:

    • Solid Organ Transplant

    Therapeutic Area:

    • Nephrology